JP Morgan Maintains Overweight on Day One Biopharmaceutical, Lowers Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama maintains an Overweight rating on Day One Biopharmaceutical (NASDAQ:DAWN) but lowers the price target from $38 to $36.
August 06, 2024 | 4:16 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan analyst Anupam Rama maintains an Overweight rating on Day One Biopharmaceutical but lowers the price target from $38 to $36.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. The net impact is likely neutral in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100